Abivax (ABVX) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ABVX · Stock Price

USD 126.54+119.69 (+1747.30%)

Market Cap: $10.0B

Historical price data

Market Cap: $10.0BPipeline: 22 drugs (6 Phase 3)Patents: 20HQ: Paris, France

Sector Ranking#105 in Small Molecule Drugs

Overview

Abivax is a clinical-stage biotech focused on developing first-in-class oral therapies that modulate the immune system via microRNA-124 enhancement. Its lead asset, obefazimod, has demonstrated positive Phase 3 induction results in ulcerative colitis, positioning it as a potential novel therapeutic with a unique mechanism. The company's strategy leverages its proprietary platform to expand into other inflammatory indications like Crohn's disease while exploring follow-on compounds from its chemical library. With a public listing on Euronext Paris and a valuation over $8B, Abivax is approaching key clinical and regulatory milestones that could validate its platform and drive future growth.

Inflammatory Bowel DiseaseChronic Inflammatory DiseasesAutoimmune Diseases

Technology Platform

Proprietary platform focused on enhancing microRNA-124 (miR-124), a natural regulator of the immune system, to restore homeostasis in inflammatory conditions via an oral small molecule approach.

Pipeline

22

22 drugs in pipeline6 in Phase 3

Drug	Indication	Stage
ABX464 + Placebo	Ulcerative Colitis	Phase 3
ABX464 + Placebo	Ulcerative Colitis	Phase 3
ABX464 + Placebo	Ulcerative Colitis	Phase 3
ABX464 + Placebo	COVID-19	Phase 2/3
ABX203 therapeutic Hepatitis B vaccine treatment arm	Chronic Hepatitis B	Phase 2/3

Funding History

4

Total raised:$215M

Venture$130MUndisclosedFeb 22, 2023

Series B$50MSofinnova PartnersJun 15, 2017

IPOUndisclosedUndisclosedOct 15, 2015

Series A$35MKurma PartnersJun 15, 2014

Opportunities

Obefazimod's novel oral mechanism targeting immune homeostasis addresses significant unmet needs in multi-billion dollar markets like ulcerative colitis and Crohn's disease.

Positive Phase 3 data could enable rapid market penetration and provide validation for expanding into other chronic inflammatory indications, creating a pipeline-in-a-product opportunity.

Risk Factors

The company faces binary clinical risk with upcoming Phase 3 data readouts, regulatory uncertainty, and intense competition from established biologics and oral therapies.

As a pre-revenue company, future capital needs for commercialization pose dilution risk, and execution of a first-ever launch presents significant operational challenges.

Competitive Landscape

Abivax competes in a crowded IBD market dominated by large pharma with biologics and newer oral JAK/S1P inhibitors. Its primary differentiation is its first-in-class miR-124 mechanism, which aims for immune stabilization rather than suppression, and its oral dosing. Success hinges on demonstrating superior or differentiated efficacy/safety versus entrenched competitors.